<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="linger. Decisions regarding initiation or continuation of disease-modifying therapy for" exact="multiple sclerosis" post="have to consider the potential relevance to the pandemic."/>
 <result pre="More importantly, the impact of each agent on the future" exact="severe acute respiratory syndrome" post="coronavirus type-2 (SARS-CoV-2) vaccine should be carefully considered in"/>
 <result pre="vaccine should be carefully considered in treatment decisions. Moreover, some" exact="multiple sclerosis" post="therapies may have beneficial antiviral effects against SARS-CoV-2 while"/>
 <result pre="increased exposure risk and therefore may be suitable for mild" exact="multiple sclerosis" post="during the pandemic. However, moderate and highly active multiple"/>
 <result pre="multiple sclerosis during the pandemic. However, moderate and highly active" exact="multiple sclerosis" post="will continue to require treatment with oral or intravenous"/>
 <result pre="where lockdown has been removed or ameliorated. Patients with iatrogenic" exact="hypogammaglobulinemia" post="may require prophylactic intravenous immunoglobulin therapy in certain situations."/>
 <result pre="situations. When the future SARS-CoV-2 vaccine becomes available, patients with" exact="multiple sclerosis" post="should be advised that certain therapies may interfere with"/>
 <result pre="required after vaccination. They should also be aware that most" exact="multiple sclerosis" post="therapies are incompatible with live vaccines if a live"/>
 <result pre="to disease-modifying therapy during the COVID-19 pandemic. Key Points Some" exact="multiple sclerosis" post="therapeutics may increase the risk of SARS-CoV-2 infection. Some"/>
 <result pre="sclerosis therapeutics may increase the risk of SARS-CoV-2 infection. Some" exact="multiple sclerosis" post="therapeutics may have a negative impact on the future"/>
 <result pre="impact on the future SARS-CoV-2 vaccine. Clinicians should carefully select" exact="multiple sclerosis" post="therapeutics during the COVID-19 pandemic and may implement some"/>
 <result pre="mitigation strategies. Introduction Coronavirus disease 2019 (COVID-19), caused by the" exact="severe acute respiratory syndrome" post="coronavirus type-2 (SARS-CoV-2), has quickly become a global pandemic"/>
 <result pre="virus based on reports of severe infection in patients with" exact="hypogammaglobulinemia" post="due to common variable immune deficiency [12]. The difference"/>
 <result pre="the immune response can lead to immune-mediated lung damage, sepsis," exact="acute respiratory distress syndrome," post="and even death [2, 14]. Future Vaccines Against SARS-CoV-2"/>
 <result pre="neuronal inflammation. Side effects may include rare leukopenia, lymphopenia, and" exact="lymphadenopathy" post="[22, 23]. Infectious Side Effects Upper respiratory tract infections"/>
 <result pre="IFN-β treatment in patients with newly diagnosed MS. Based on" exact="influenza" post="vaccine studies, IFN-β does not seem to reduce the"/>
 <result pre="of overall infection (30% vs 28%), bronchitis (6% vs 5%)," exact="influenza" post="(14% vs 13%), nasopharyngitis (11% vs 9%), and viral"/>
 <result pre="vs 28%), bronchitis (6% vs 5%), influenza (14% vs 13%)," exact="nasopharyngitis" post="(11% vs 9%), and viral URTIs (3% vs 2%)"/>
 <result pre="potential negative impact on the protective immune response to the" exact="influenza" post="vaccine in patients taking GA but several other studies"/>
 <result pre="lymphocytes [29]. Immune side effects include rare lymphopenia (12%) and" exact="neutropenia" post="(16%) [36]. Infectious Side Effects Teriflunomide 14 mg had"/>
 <result pre="including URTIs (9% vs 7%), bronchitis (8% vs 6%), and" exact="sinusitis" post="(6% vs 4%) [36]. Rare cases of tuberculosis were"/>
 <result pre="6%), and sinusitis (6% vs 4%) [36]. Rare cases of" exact="tuberculosis" post="were also seen. There have also been reports of"/>
 <result pre="but the patient had advanced secondary progressive MS and comorbid" exact="myotonic dystrophy" post="[38]. Seven other cases of COVID-19 infection in patients"/>
 <result pre="paper surveying self-reported cases on social media [42]. Based on" exact="influenza" post="vaccine studies, teriflunomide is unlikely to reduce the protective"/>
 <result pre="experiencing lymphopenia [48]. However, there have been case reports of" exact="progressive multifocal leukoencephalopathy" post="(PML) reported with DMF mainly in patients with prolonged"/>
 <result pre="of PML. Respiratory infections including URTIs (22% vs 16% placebo)," exact="influenza" post="(12% vs 5% placebo), and sinusitis (8% vs 4%"/>
 <result pre="(22% vs 16% placebo), influenza (12% vs 5% placebo), and" exact="sinusitis" post="(8% vs 4% placebo) were commonly observed in patients"/>
 <result pre="observed in patients taking natalizumab [64]. Fatal cases of herpetic" exact="encephalitis" post="and meningitis were reported in the post-marketing data. Potential"/>
 <result pre="patients taking natalizumab [64]. Fatal cases of herpetic encephalitis and" exact="meningitis" post="were reported in the post-marketing data. Potential Relevance to"/>
 <result pre="proposed via its action on integrin receptors [6]. Based on" exact="influenza" post="vaccine studies, it is also unlikely that natalizumab will"/>
 <result pre="the CNS also raises concerns about the potential for SARS-CoV-2" exact="encephalitis" post="if natalizumab is used in patients with COVID-19 [66]."/>
 <result pre="cells, prolonged depletion of memory B cells can lead to" exact="hypogammaglobulinemia" post="in some patients as seen with other B-cell therapies"/>
 <result pre="vs 33%), lower respiratory tract infection (LRTI) (8% vs 5%)," exact="herpes zoster" post="(2.1% vs 1.0%), and herpes simplex (0.7% vs 0.1%)"/>
 <result pre="(LRTI) (8% vs 5%), herpes zoster (2.1% vs 1.0%), and" exact="herpes simplex" post="(0.7% vs 0.1%) were also higher in the ocrelizumab-treated"/>
 <result pre="may predispose recovering patients to repeated infection. Patients with ocrelizumab-related" exact="hypogammaglobulinemia" post="may be particularly vulnerable to infection-related risks [72]. Acquired"/>
 <result pre="hypogammaglobulinemia may be particularly vulnerable to infection-related risks [72]. Acquired" exact="hypogammaglobulinemia" post="in patients treated with anti-CD20 agents resembles the immune"/>
 <result pre="with intravenous immunoglobulin should be considered in patients with severe" exact="hypogammaglobulinemia" post="as a prophylactic measure in uninfected patients and to"/>
 <result pre="of T cells, alemtuzumab can cause several autoimmune disorders including" exact="thyroid disease," post="idiopathic thrombocytopenia, and glomerulonephritis. Alemtuzumab also alters the innate"/>
 <result pre="CD52-positive macrophages and dendritic cells [85]. It can also cause" exact="neutropenia" post="and pancytopenia. Infectious Side Effects Patients treated with alemtuzumab"/>
 <result pre="vs 53% of patients taking IFN-β1a [86]. These infections included" exact="nasopharyngitis" post="(25% vs 19%), URTIs (16% vs 13%), sinusitis (11%"/>
 <result pre="infections included nasopharyngitis (25% vs 19%), URTIs (16% vs 13%)," exact="sinusitis" post="(11% vs 8%), herpetic infections (16% vs 3%), influenza"/>
 <result pre="13%), sinusitis (11% vs 8%), herpetic infections (16% vs 3%)," exact="influenza" post="(8% vs 6%), and bronchitis (7% vs 4%). Serious"/>
 <result pre="taking alemtuzumab vs 1% of patients taking IFN-β1a. These included" exact="pneumonia" post="and herpes zoster. Potential Relevance to the COVID-19 Pandemic"/>
 <result pre="vs 1% of patients taking IFN-β1a. These included pneumonia and" exact="herpes zoster." post="Potential Relevance to the COVID-19 Pandemic and Possible Risk"/>
 <result pre="infection is the link between alemtuzumab and the risk of" exact="stroke" post="and cervicocephalic arterial dissection [92, 93]. This might augment"/>
 <result pre="the innate immune cells is limited, although rare cases of" exact="neutropenia" post="and pancytopenia have been described. Lymphocyte counts are monitored"/>
 <result pre="immune cells is limited, although rare cases of neutropenia and" exact="pancytopenia" post="have been described. Lymphocyte counts are monitored regularly prior"/>
 <result pre="in the placebo group. There was a higher incidence of" exact="herpes zoster" post="infections in patients with severe lymphopenia of less than"/>
 <result pre="with severe lymphopenia of less than 500/mm3. Severe and fatal" exact="tuberculosis" post="and hepatitis B infections have occurred with cladribine. Potential"/>
 <result pre="lymphopenia of less than 500/mm3. Severe and fatal tuberculosis and" exact="hepatitis" post="B infections have occurred with cladribine. Potential Relevance to"/>
 <result pre="risk mitigation strategies Interferon-beta Modulate T/B cells and cytokines Rare" exact="leukopenia" post="and lymphadenopathy Once weekly IM, once every 2 weeks"/>
 <result pre="strategies Interferon-beta Modulate T/B cells and cytokines Rare leukopenia and" exact="lymphadenopathy" post="Once weekly IM, once every 2 weeks SC, 3"/>
 <result pre="continue – Teriflunomide Decrease proliferation of reactive lymphocytes Rare lymphopenia," exact="neutropenia" post="Once daily orally May increase susceptibility Possible antiviral effect"/>
 <result pre="are JCV antibody negative No, may continue but monitor for" exact="encephalitis" post="Consider an extended-dosing interval to reduce exposure risk Ocrelizumab"/>
 <result pre="reduce exposure risk Ocrelizumab Anti-CD20 causing selective B-cell depletion Lymphopenia," exact="hypogammaglobulinemia" post="6-monthly infusions May increase susceptibility and reinfection risk –"/>
 <result pre="deficiency Check post-vaccination serology Alemtuzumab Anti-CD52 causing non-selective lymphopenia Neutropenia," exact="pancytopenia" post="Daily IV for 5 days then daily IV for"/>
 <result pre="causing non-selective lymphopenia with more impact on B cells Neutropenia," exact="pancytopenia" post="Oral: two courses 1 year apart each made of"/>
 <result pre="John Cunningham virus, MHC major histocompatibility complex, PPMS primary progressive" exact="multiple sclerosis," post="RMS relapsing multiple sclerosis, S1P sphingosine-1-phosphate, SARS-CoV-2 severe acute"/>
 <result pre="major histocompatibility complex, PPMS primary progressive multiple sclerosis, RMS relapsing" exact="multiple sclerosis," post="S1P sphingosine-1-phosphate, SARS-CoV-2 severe acute respiratory syndrome coronavirus type-2,"/>
 <result pre="progressive multiple sclerosis, RMS relapsing multiple sclerosis, S1P sphingosine-1-phosphate, SARS-CoV-2" exact="severe acute respiratory syndrome" post="coronavirus type-2, SC subcutaneously Fig. 1 Proposed practical approach"/>
 <result pre="Ig immunoglobulin, IVIG intravenous immunoglobulins, JCV John Cunningham virus, MS" exact="multiple sclerosis" post="Declarations Funding No sources of funding were received for"/>
 <result pre="on the mechanism of cytokine storm induced by new coronavirus" exact="pneumonia" post="and related immunotherapyZhonghua Shao Shang Za Zhi202036E005 8.VabretNBrittonGJGruberCet al.Immunology"/>
 <result pre="elicited by SARS-CoV-2 infectionNature202032454513 11.SoresinaAMorattoDChiariniMet al.Two X-linked agammaglobulinemia patients develop" exact="pneumonia" post="as COVID-19 manifestation but recoverPediatr Allergy Immunol202032319118 12.QuintiILougarisVMilitoCet al.A"/>
 <result pre="phase 2 trialLancet2020395102381695170432401715 26.SchwidSRDeckerMDLopez-BresnahanMcollab: Rebif-Influenza Vaccine Study InvestigatorsImmune response to" exact="influenza" post="vaccine is maintained in patients with multiple sclerosis receiving"/>
 <result pre="InvestigatorsImmune response to influenza vaccine is maintained in patients with" exact="multiple sclerosis" post="receiving interferon beta-1aNeurology200565121964196616380621 27.CohenJABarkhofFComiGet al.Oral fingolimod or intramuscular interferon"/>
 <result pre="https://www.copaxone.com/globalassets/copaxone/prescribing-information.pdf. Accessed 28 July 2020. 31.PellegrinoPCarnovaleCPerroneVet al.Efficacy of vaccination against" exact="influenza" post="in patients with multiple sclerosis: the role of concomitant"/>
 <result pre="and predictors of response to a single dose trivalent seasonal" exact="influenza" post="vaccine in multiple sclerosis patients receiving disease-modifying therapiesCNS Neurosci"/>
 <result pre="response to a single dose trivalent seasonal influenza vaccine in" exact="multiple sclerosis" post="patients receiving disease-modifying therapiesCNS Neurosci Ther201925224525430044050 33.OlbergHKEideGECoxRJet al.Antibody response"/>
 <result pre="receiving disease-modifying therapiesCNS Neurosci Ther201925224525430044050 33.OlbergHKEideGECoxRJet al.Antibody response to seasonal" exact="influenza" post="vaccination in patients with multiple sclerosis receiving immunomodulatory therapyEur"/>
 <result pre="33.OlbergHKEideGECoxRJet al.Antibody response to seasonal influenza vaccination in patients with" exact="multiple sclerosis" post="receiving immunomodulatory therapyEur J Neurol201825352753429205701 34.FoxRJMillerDHPhillipsJTet al.Placebo controlled, phase"/>
 <result pre="symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to" exact="multiple sclerosis" post="relapseJ Neurol202032494855 41.LucaBTommasoGBavaroDFet al.Seroconversion and indolent course of COVID-19"/>
 <result pre="41.LucaBTommasoGBavaroDFet al.Seroconversion and indolent course of COVID-19 in patients with" exact="multiple sclerosis" post="treated with fingolimod and teriflunomideJ Neurol Sci202041611701132650143 42.NesbittCRathLYehWZet al.MSCOVID19:"/>
 <result pre="Scler Relat Disord20204510233832629402 43.Bar-OrAFreedmanMSKremenchutzkyMet al.Teriflunomide effect on immune response to" exact="influenza" post="vaccine in patients with multiple sclerosisNeurology201381655255823851964 44.O’ConnorPWolinskyJSConfavreuxCet al.Randomized trial"/>
 <result pre="Engl J Med2011365141293130321991951 45.ConfavreuxCO’ConnorPComiGet al.Oral teriflunomide for patients with relapsing" exact="multiple sclerosis" post="(TOWER): a randomized, double-blind, placebo-controlled, phase 3 trialLancet Neurol201413324725624461574"/>
 <result pre="October 2019. https://www.vumerityhcp.com/content/dam/commercial/vumerity/hcp/en_us/pdf/vumerity-prescribing-information.pdf. Accessed 28 July 2020. 49.DieboldMAltersbergerVDécardBFKapposLDerfussTLorscheiderJA case of" exact="progressive multifocal leukoencephalopathy" post="under dimethyl fumarate treatment without severe lymphopenia or immunosenescenceMult"/>
 <result pre="al.Safety and efficacy of ozanimod versus interferon beta-1a in relapsing" exact="multiple sclerosis" post="(RADIANCE): a multicentre, randomised, 24-month, phase 3 trialLancet Neurol201918111021103331492652"/>
 <result pre="57.Valencia-SanchezCWingerchukDMA fine balance: immunosuppression and immunotherapy in a patient with" exact="multiple sclerosis" post="and COVID-19Mult Scler Relat Disord20204210218232416330 58.FoxEJBuckleGJSingerBSinghVBosterALymphopenia and DMTs for"/>
 <result pre="management considerationsNeuro Ther20198241250 60.BarzegarMMirmosayyebONehzatNet al.COVID-19 infection in a patient with" exact="multiple sclerosis" post="treated with fingolimodNeurol Neuroimmunol Neuroinflamm202074e75332371550 61.FoerchCFriedauerLBauerBWolfTAdamEHSevere COVID-19 infection in"/>
 <result pre="fingolimodNeurol Neuroimmunol Neuroinflamm202074e75332371550 61.FoerchCFriedauerLBauerBWolfTAdamEHSevere COVID-19 infection in a patient with" exact="multiple sclerosis" post="treated with fingolimodMult Scler Relat Disord20204210218032408155 62.ChiariniMPagheraSMorattoDet al.Immunologic characterization"/>
 <result pre="fingolimodMult Scler Relat Disord20204210218032408155 62.ChiariniMPagheraSMorattoDet al.Immunologic characterization of a immunosuppressed" exact="multiple sclerosis" post="patient that recovered from SARS-CoV-2 infectionJ Neuroimmunol202034557728232505908 63.KapposLMehlingMArroyoRet al.Randomized"/>
 <result pre="2019. https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf?cid=PPC-MICROSOFT-Tysabri_DTC_Branded_Phrase~S~PH~BR~NER~DTC~BR-natalizumab-NA-p31547638597&amp;amp;&amp;amp;msclkid=ba0b5edf571d1d26140801cd7edd34cb&amp;amp;gclid=ba0b5edf571d1d26140801cd7edd34cb&amp;amp;gclsrc=3p.ds. Accessed 28 July 2020. 65.VågbergMKumlinUSvenningssonAHumoral immune response to" exact="influenza" post="vaccine in natalizumab-treated MS patientsNeurol Res201234773073322709910 66.GiovannoniGHawkesCLechner-ScottJLevyMWaubantEGoldJThe COVID-19 pandemic"/>
 <result pre="approachMult Scler Relat Disord20204110216532388451 69.AguirreCMeca-LallanaVBarrios-BlandinoADel RíoBVivancosJCovid-19 in a patient with" exact="multiple sclerosis" post="treated with natalizumab: may the blockade of integrins have"/>
 <result pre="infections in the pivotal phase III trials of ocrelizumab in" exact="multiple sclerosis" post="and their open-label extensions. Paper presented at the 2019"/>
 <result pre="may affect susceptibility to acute respiratory illness among patients with" exact="multiple sclerosis" post="during the early COVID-19 epidemic in IranMult Scler Relat"/>
 <result pre="COVID-19 epidemic in IranMult Scler Relat Disord20204310219532460086 76.Meca-LallanaVAguirreCRíoBCardeñosoLAlarconTVivancosJCOVID-19 in 7" exact="multiple sclerosis" post="patients in treatment with ANTI-CD20 therapiesMult Scler Relat Disord20204410230632585617"/>
 <result pre="with hypogammaglobulinemiaMult Scler Relat Disord20204410231532593144 80.Van AssenSHolvastABenneCAet al.Humoral responses after" exact="influenza" post="vaccination are severely reduced in patients with rheumatoid arthritis"/>
 <result pre="responses after influenza vaccination are severely reduced in patients with" exact="rheumatoid arthritis" post="treated with rituximabArthritis Rheum201062758120039396 81.HughesRPedottiRKoendgenHCOVID-19 in persons with multiple"/>
 <result pre="after influenza vaccination are severely reduced in patients with rheumatoid" exact="arthritis" post="treated with rituximabArthritis Rheum201062758120039396 81.HughesRPedottiRKoendgenHCOVID-19 in persons with multiple"/>
 <result pre="rheumatoid arthritis treated with rituximabArthritis Rheum201062758120039396 81.HughesRPedottiRKoendgenHCOVID-19 in persons with" exact="multiple sclerosis" post="treated with ocrelizumab: a pharmacovigilance case seriesMult Scler Relat"/>
 <result pre="pharmacovigilance case seriesMult Scler Relat Disord202032570202 82.Montero-EscribanoPMatías-GuiuJGómez-IglesiasPPorta-EtessamJPytelVMatias-GuiuJAAnti-CD20 and COVID-19 in" exact="multiple sclerosis" post="and related disorders: a case series of 60 patients"/>
 <result pre="Relat Disord20204210212032315980 84.GhajarzadehMMirmosayyebOBarzegarMet al.Favorable outcome after COVID-19 infection in a" exact="multiple sclerosis" post="patient initiated on ocrelizumab during the pandemicMult Scler Relat"/>
 <result pre="28 July 2020. 87.GuevaraCVillaECifuentesMNavesRGraziaJMild COVID-19 infection in a patient with" exact="multiple sclerosis" post="and severe depletion of T-lymphocyte subsets due to alemtuzumabMult"/>
 <result pre="subsets due to alemtuzumabMult Scler Relat Disord20204410231432593959 88.CarandiniTPietroboniAMSacchiLet al.Alemtuzumab in" exact="multiple sclerosis" post="during the COVID-19 pandemic: a mild uncomplicated infection despite"/>
 <result pre="intense immunosuppressionMult Scler202032463329 89.Matías-GuiuJMontero-EscribanoPPytelVPorta-EtessamJMatias-GuiuJAPotential COVID-19 infection in patients with severe" exact="multiple sclerosis" post="treated with alemtuzumabMult Scler Relat Disord20201144102297 90.BrownleeWBourdetteDBroadleySKillesteinJCiccarelliOTreating multiple sclerosis"/>
 <result pre="severe multiple sclerosis treated with alemtuzumabMult Scler Relat Disord20201144102297 90.BrownleeWBourdetteDBroadleySKillesteinJCiccarelliOTreating" exact="multiple sclerosis" post="and neuromyelitis optica spectrum disorder during the COVID-19 pandemicNeurology2020942294995232241953"/>
 <result pre="treated with alemtuzumabMult Scler Relat Disord20201144102297 90.BrownleeWBourdetteDBroadleySKillesteinJCiccarelliOTreating multiple sclerosis and" exact="neuromyelitis optica" post="spectrum disorder during the COVID-19 pandemicNeurology2020942294995232241953 91.https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-/116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf. Accessed 10"/>
 <result pre="Safety Communication. FDA warns about rare but serious risks of" exact="stroke" post="and blood vessel wall tears with multiple sclerosis drug"/>
 <result pre="serious risks of stroke and blood vessel wall tears with" exact="multiple sclerosis" post="drug Lemtrada (alemtuzumab). https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm. Accessed 10 July 2020. 94.OxleyTJMoccoJMajidiSet"/>
 <result pre="drug Lemtrada (alemtuzumab). https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm. Accessed 10 July 2020. 94.OxleyTJMoccoJMajidiSet al.Large-vessel" exact="stroke" post="as a presenting feature of Covid-19 in the youngN"/>
 <result pre="Neurol Disord201912175628641985498631244898 99.Dalla CostaGLeocaniLMontalbanXet al.Real-time assessment of COVID-19 prevalence among" exact="multiple sclerosis" post="patients: a multicenter European studyNeurol Sci202032617741 100.SormaniMPItalian Study Group"/>
 <result pre="European studyNeurol Sci202032617741 100.SormaniMPItalian Study Group on COVID-19 infection in" exact="multiple sclerosis." post="An Italian programme for COVID-19 infection in multiple sclerosis"/>
 <result pre="in multiple sclerosis. An Italian programme for COVID-19 infection in" exact="multiple sclerosis" post="[published correction appears in Lancet Neurol. 2020 May 28]Lancet"/>
</results>
